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ABSTRACT
Nrf2 is a transcription factor that regulates cellular stress response and 
irinotecan-metabolising pathways. Its aberrant activity has been reported in a 
number of cancers, although relatively few studies have explored a role for Nrf2 
in colorectal cancer (CRC). This study assessed the expression of Nrf2 in patient 
CRC tissues and explored the effect of Nrf2 modulation alone, or in combination 
with irinotecan, in human (HCT116) and murine (CT26) cell lines in vitro and in 
an orthotopic syngeneic mouse model utilising bioluminescent imaging. Using a 
tissue microarray, Nrf2 was found to be overexpressed (p<0.01) in primary CRC 
and metastatic tissue relative to normal colon, with a positive correlation between 
Nrf2 expression in matched primary and metastatic samples. In vitro experiments in 
CRC cell lines revealed that Nrf2 siRNA and brusatol, which is known to inhibit Nrf2, 
decreased viability and sensitised cells to irinotecan toxicity. Furthermore, brusatol 
effectively abrogated CRC tumour growth in subcutaneously and orthotopically-
allografted mice, resulting in an average 8-fold reduction in luminescence at the 
study end-point (p=0.02). Our results highlight Nrf2 as a promising drug target in 
the treatment of CRC.
INTRODUCTION
Colorectal cancer (CRC) continues to be the second 
leading cause of cancer-related death in the Western World, 
with the worst outcomes in patients with metastatic disease 
(mCRC) [1]. Neoadjuvant chemotherapy can bring patients 
with mCRC to resection, while in the adjuvant setting it 
can treat systemic disease. First-line treatment varies with 
geographical location, in the US the FOLFIRI regimen 
(5-flurouracil, leucovorin and Irinotecan) predominates. 
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In the UK, irinotecan-based regimens are more commonly 
employed in the management of patients with advanced 
disease who have failed with oxaliplatin based therapy. 
Chemotherapy-response varies significantly, disease 
progression is common, while debilitating side-effects or 
systemic toxicity can limit treatment [2]. The development 
of novel therapies is essential and is achieved through 
the identification of drug-targetable molecular pathways 
involved in cancer cell survival or chemo-resistance.
Nuclear factor-erythroid 2-related factor 2 (Nrf2) is 
a transcription factor that, amongst other roles, regulates 
the expression of drug metabolising and antioxidant 
genes and confers cytoprotection against cellular stress. 
Under basal conditions Nrf2 is sequestered by kelch-like 
ECH-associated protein 1 (Keap1), which promotes its 
degradation in the proteasome. Studies have implicated 
Nrf2 in cancer cell survival and chemo-resistance, with 
an increasing number of reports of its constitutive over-
expression in a number of malignancies [3, 4]. As a result, 
there is interest in the therapeutic potential of modulating 
Nrf2 activity in the context of CRC and other cancers.
Nrf2 plays an important role in drug disposition, 
with potential consequences for the efficacy of 
chemotherapeutic agents, particularly irinotecan. 
Irinotecan is a water-soluble pro-drug converted to the 
active metabolite SN-38, which inhibits topoisomerase 
I [5]. Nrf2 regulates the expression of the human 
carboxylesterases [6], required for the hydrolysis of 
irinotecan to SN-38 [7–9], in addition to regulating the 
expression of UGT1A1, responsible for deactivation 
of SN-38 by glucuronidation [10, 11]. Any therapeutic 
strategy involving Nrf2 manipulation needs to consider 
both the direct impact on tumour development and 
any indirect, and potentially undesirable, effects due 
to altered metabolism or transport of co-administered 
chemotherapeutics.
The availability of pharmacological inducers and 
inhibitors of Nrf2 offers the possibility of modulating this 
pathway in the clinical setting. The synthetic triterpenoid, 
methyl-2-cyano-3,12-dioxooleano-1,9-dien-28-oate 
(CDDO-me), is a potent inducer of Nrf2. CDDO-me is a 
derivative of oleanolic acid demonstrated to increase Nrf2 
activity [12]. Brusatol is a naturally occurring quassinoid 
extracted from the aerial parts of the Brucea javanica plant 
that has been shown to inhibit Nrf2 [13–15]. Fruit and 
seed oil from the Brucea javanica plant have traditionally 
been used in Chinese medicine [16], whilst brusatol has 
been shown to overcome chemoresistance in both in vitro 
and in vivo models of lung cancer [15, 17].
The effect of Nrf2 modulation in the management 
of CRC is unpredictable, particularly in the context of 
irinotecan cytotoxicity, due to complex interactions 
between drug metabolism and cell survival pathways. 
With approximately 50% of irinotecan converted to SN-
38 in the liver, understanding the interaction between 
tumour and host is key, making in vivo assessment 
essential [9]. Here, we provide evidence for the elevated 
expression of Nrf2 in CRC tumour tissue, compared 
with matched normal colonic mucosa, and demonstrate a 
positive correlation between Nrf2 expression in matched 
CRC primary and metastatic tissue. We demonstrate 
that modulation of Nrf2 can sensitise CRC cells to the 
cytotoxic effects of irinotecan in vitro, and that brusatol 
can inhibit tumour growth in a syngeneic orthotopic 
mouse model of CRC. Our findings highlight Nrf2 as a 
potential drug target in the treatment of CRC.
RESULTS
Nrf2 is upregulated in CRC patient samples
Fifty-nine patients with mCRC were included in 
the tissue microarray, 50 (85%) with cores of primary 
CRC, 43 (73%) with cores of liver metastases and 34 
(58%) with normal colon available. Matched primary and 
metastatic samples were available for 34 (58%) patients. 
Clinicopathological details of the patients are included 
in Table 1. Nrf2 expression was significantly higher 
in primary and metastatic CRC samples than in normal 
colon (Figure 1A and 1B). Nrf2 expression did not alter 
significantly with sex, T stage or N stage (Supplementary 
Table 1). A positive correlation was noted between 
the Nrf2 H-scores of matched primary and metastatic 
samples (Figure 1C), indicating that Nrf2 expression in 
the metastasis reflects that of the primary tumour. There 
was no difference in Nrf2 expression in the primary 
(Figure 1D) or metastatic samples (Figure 1E) of chemo-
naïve patients when compared to those who received 
neoadjuvant chemotherapy, suggesting the observed high 
expression of Nrf2 was not simply a marker of increased 
cellular stress induced by chemotherapy.
Inhibition of Nrf2 reduces CRC cell viability and 
proliferative capacity
To explore the effect of Nrf2 modulation on CRC 
cell growth, studies were conducted in human (HCT116) 
and murine (CT26) CRC-derived cell lines. Levels of 
Nrf2 were modulated either by genetic silencing of 
Nrf2 or Keap1 utilising siRNA (Figure 2A and 2B) or 
pharmacologically with the potent inducer CDDO-me or 
with brusatol, which is known to inhibit Nrf2 (Figure 2C 
and 2D). A higher concentration of brusatol was required 
to significantly inhibit Nrf2 in CT26 cells compared with 
HCT-116 cells. In both cell lines, and consistent with 
previous reports [13, 15], brusatol-mediated inhibition of 
Nrf2 was transient, with maximum inhibition observed 
at three hours (Figure 2E and 2F). The effects of Nrf2 
inhibition on the downstream target Nqo1 are displayed in 
Supplementary Figure 2.
siRNA inhibition of Nrf2 resulted in a 14% and 23% 
reduction in cell viability in HCT116 (Figure 3A) and CT26 
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(Figure 3B) cells respectively, establishing a role for Nrf2 in 
the survival of CRC cells. The opposite trend was noted for 
activation of Nrf2 through Keap1 inhibition in HCT116 cells, 
with an increase in viability of 21% (Figure 3A); there was 
a non-significant 7% increase in the viability of CT26 cells 
transfected with Keap1 siRNA (Figure 3B). The modulation 
of the known Nrf2 target Nqo1 confirmed the altered 
activity of the Nrf2 pathway in cells transfected with siRNA 
(Supplementary Figure 2). Brusatol also reduced viability 
in both cancer cell lines, while in HCT116 cells CDDO-me 
slightly increased cell viability in a concentration-dependent 
manner (Figure 3C). The effect of CDDO-me was not noted 
in the CT26 cells (Figure 3C), which have higher basal 
expression of Nrf2. In benign human CCD-33Co colonic 
cells, the effects of CDDO-me and brusatol on viability were 
less marked than in CRC cells (Figure 3C). Finally, to assess 
the effect of brusatol on CRC cell proliferation, clonogenic 
assays were performed. Brusatol reduced colony formation 
and the surviving fraction in both CRC cell lines, with IC50 
values of 21nM (95% CI, 19-23nM) and 373nM (95% 
CI, 277-502nM) in HCT116 and CT26 cells respectively, 
suggesting a reduced proliferative capacity following brusatol 
treatment (Figure 3D and 3E).
Nrf2 inhibition sensitises CRC cells to irinotecan
Having demonstrated that modulation of Nrf2 
affects CRC cell viability and proliferative capacity, it 
was important to ensure that Nrf2 modulation did not 
negatively impact the efficacy of chemotherapeutics. The 
effect of siRNA or pharmacological modulation of Nrf2 
on the cytotoxicity of irinotecan was assessed in HCT116 
and CT26 cells. Both Nrf2 siRNA (Figure 4A and 4B) 
and brusatol (Figure 4C and 4D) significantly decreased 
the IC50 of irinotecan in the CRC cell lines, signifying 
increased sensitivity to irinotecan following Nrf2 
depletion. The cytoprotective effect of Nrf2 activation 
was again more marked in the HCT116 cell line than in 
CT26 cells (Figure 4C and 4D), potentially indicating a 
biological limit to the protective effect of activation of 
the Nrf2 pathway. Combination indices demonstrated a 
synergistic enhanced cytotoxic response when brusatol 
and irinotecan were co-incubated with the CRC cell 
lines (Figure 4E and 4F). In contrast, when brusatol and 
irinotecan were applied to benign CCD-33Co cells the 
effect was found to be mostly additive, with little drug 
synergy evident (Supplementary Figure 3). Co-treatment 
of the CRC cell lines with brusatol also reduced the IC50 
of 5-flurouracil, although drug synergy was achieved 
at fewer concentrations than noted with irinotecan 
(Supplementary Figure 4), possibly due to a differential 
influence of Nrf2 on the metabolism of 5-flurouracil.
Brusatol reduces CRC disease burden and 
improves the efficacy of irinotecan therapy in vivo
Based on the in vitro findings, the therapeutic 
potential of brusatol was assessed in vivo following the 






Normal Colon P value
Median age (range) 78 (40-98) 78 (40-98) 79 (40-98) p = 0.834 (ANOVA)
Gender (%) Male 35 (70) 29 (67) 23 (68) p = 0.958 (Chi-Square)
Female 15 (30) 14 (33) 11 (32)
T stage (%) 1 0 0 0 p = 0.911 (Chi-Square)
2 8 (16) 4 (9) 4 (13)
3 33 (66) 31 (72) 24 (71)
4 9 (18) 8 (19) 6 (18)
N stage (%) 0 14 (28) 11 (26) 11 (23) p = 0.486 (Chi-Square)
1 26 (52) 25 (58) 21 (62)
2 10 (20) 7 (16) 2 (6)
Chemotherapy (%) Yes 31 (62) 22 (51) 22 (65) p = 0.597 (Chi-Square)
No 17 (34) 17 (40) 11 (32)
Unknown 2 (4) 4 (9) 1 (3)
Total 50 43 34
There were no statistically significant differences between patients variables included in the analysis of available tissue cores.
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Figure 1: Nrf2 expression in patient samples. (A) Mean Nrf2 expression, measured by the calculation of H-scores, was significantly 
higher in primary (H-score = 30) and metastatic (H-score = 43) tumour tissue than normal colon (H-score 6, Kruskal-Wallis with Dunn’s 
multiple comparisons test). (B) Examples of tissue cores as analysed by Tissue Studio v.2.0 showing cellular recognition (green for 
cytoplasm and blue for nucleus) and Nrf2 staining intensity as assigned by the software; white represents negative, yellow weakly positive, 
orange moderately positive and red strongly positive cells. (C) A positive correlation in Nrf2 expression was confirmed between matched 
primary tumour and liver metastases in patient samples (r=0.4, p=0.03, Pearson’s R correlation). Comparison of H-scores in chemo-naïve 
and treated patients showed no significant difference in Nrf2 expression in primary (D) or metastatic tissue (E) (Mann-Whitney test). 
Graphs display mean with 95% confidence interval.
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Figure 2: Western blot confirmation of Nrf2 modulation in HCT116 (A) and CT26 (B) cells using siRNA targeting Nrf2 or Keap1 and 
pharmacologically with brusatol or CDDO-me in HCT116 (C) and CT26 (D) cells. Significant Nrf2 inhibition required 100nM and 300nM 
of brusatol in the HCT116 and CT26 cell lines respectively while significant Nrf2 induction was demonstrated at 30nM of CDDO-me in 
both cell lines (one-way ANOVA with Holm-Sidak’s multiple comparison test). The effect of brusatol on Nrf2 was transient in HCT116 (E) 
and CT26 (F) cells with the maximum effect at three hours. CDDO-me induction resulted in upregulation of Nrf2 for greater than 24 hours. 
All graphs display mean data with error bars representing standard deviation. C= 0.5% DMSO vehicle control.
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Figure 3: Cell viability assessment in cell lines following Nrf2 modulation. siRNA inhibition of Nrf2 in HCT116 (A) and CT26 
cells (B) caused a significant decrease in viability (one-way ANOVA with Holm-Sidak’s multiple comparison test). (C) Brusatol reduced 
cell viability in a concentration-dependent manner in all cell lines, but to a lesser extent in benign CCD-33Cocolonic cells, as reflected in 
the relative IC50 values (extra sum-of-squares F test). CDDO-me induction of Nrf2 caused a small increase in proliferation of HCT116 
and CCD-33Co cells. Assessment of reproductive integrity following exposure to brusatol confirmed inhibition of colony formation, 
represented by calculation of surviving fractions expressed as a percentage of untreated cells, in HCT116 (D) and CT26 cells (E). All graphs 
display mean data with error bars representing standard deviation. C= 0.5% DMSO vehicle control.
Oncotarget27110www.oncotarget.com
Figure 4: Assessment of cell viability for the combination of irinotecan with Nrf2 modulation. Nrf2 inhibition using 
siRNA significantly increased the cytotoxicity of irinotecan in HCT116 (A) and CT26 (B) cells as reflected by the decrease IC50 values 
when compared to treatment with irinotecan alone (extra sum-of-squares F test). The cytoprotective effect of overexpression of Nrf2 by 
KEAP1 inhibition was less marked in the CT26 (B) cell line than in HCT116 (A). Pharmacological modulation of Nrf2 with brusatol and 
CDDO-me in combination with irinotecan showed the same trends as seen with siRNA transfection in both HCT116 (C) and CT26 (D) 
cells. Calculated combination indexes for treatment with irinotecan and brusatol confirm drug synergy in HCT116 (E) and CT26 (F) cells 
across a range of concentrations with red signifying a higher degree of synergy. All graphs display mean data with error bars representing 
standard deviation. IR = irinotecan.
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injection of luciferase-expressing CT26 cells, either 
into the flank or orthotopically into the caecal wall, of 
BALB/c mice. Prior to in vivo studies, brusatol dose-
response curves were generated in vitro using the 
luciferase-expressing CT26 cells to confirm phenotypic 
similarity to the parent population (Supplementary 
Figure 5). Treatment with brusatol markedly reduced the 
growth of flank tumours, as represented by fold change in 
luminescence and tumour volume in vivo (p<0.01; Figure 
5A and 5B), and tumour volume at necropsy (Figure 5C). 
Nrf2 expression in excised tumour tissue was reduced by 
74% in mice treated with brusatol compared to controls 
(p=0.03; Figure 5D). A significant reduction in tumour 
growth rate with brusatol treatment (represented by fold 
change in luminescence) was also noted in the syngeneic 
orthotopic CRC model (p<0.01; Figure 5E and 5F). 
Notably, in this model there was a trend towards enhanced 
anti-tumour efficacy in mice treated with a combination 
of brusatol and irinotecan, compared with each treatment 
in isolation (Figure 5E and 5F; Supplementary Figure 6). 
Indeed, at the final time-point the fold change in tumour 
size was significantly different in mice treated with a 
combination of irinotecan and brusatol when compared 
with irinotecan alone (mean fold change = 26.4 versus 
144.1, p=0.04, unpaired t-test with Welch correction). 
Whilst no adverse effects were noted in mice receiving 
brusatol, several mice in the control group began to exhibit 
tumour-related symptoms including ascites, weight loss 
and gastrointestinal obstruction, limiting the study end-
point. IHC staining of randomly selected caecal tumours 
demonstrated reduced Nrf2 expression in mice treated 
with brusatol (mean Nrf2 staining score = 53.3) when 
compared with the saline-treated controls (mean Nrf2 
staining score = 190; Figure 5G).
DISCUSSION
Following the discovery of Nrf2 as a master regulator 
of cellular defence [18, 19], its early therapeutic prospects 
were perceived to principally lie in chemoprevention, 
due to its ability to counteract the potentially damaging 
effects of environmental chemicals, oxidative stress and 
ionising radiation [20]. Mounting evidence revealed a 
darker side to Nrf2 in cancer, with many tumour types 
displaying elevated levels of the transcription factor, often 
due to loss-of-function mutations in the Keap1 gene that 
promote Nrf2-driven transcriptional activity [21]. Along 
with a small number of other studies in CRC patients [22, 
23], the tissue microarray performed here confirms up-
regulation of Nrf2 in primary and metastatic CRC tissue. 
Our data also agree with previous studies indicating that 
higher Nrf2 expression contributes to chemo-resistance 
in CRC cell lines, possibly due to the up-regulation of 
cytoprotective mechanisms such as glutathione and other 
antioxidant pathways, or through increased expression of 
drug export proteins and metabolising enzymes [24–26]. 
Increased Nrf2 activity in CRC may occur for a number of 
reasons: hypermethylation of the Keap1 promoter region 
is common in CRC cell lines, suppressing its mRNA 
expression [27]; somatic mutations in Keap1 were found 
in 8% of CRCs, resulting in loss of inhibitory function 
[21]; and activation of the KRAS-MEK-ERK pathway 
has been associated with high levels of Nrf2 expression in 
lung and pancreatic cancer [17, 28]. Oncogenic mutations 
in KRAS occur in 32% of CRC tumours [29] and both 
CRC cell lines used in this study are KRAS mutants [30, 
31]. These findings imply increased Nrf2 expression 
conveys a survival benefit to cancer cells, which may 
become dependent on increased Nrf2 activity.
This is the first study to demonstrate that 
brusatol can suppress tumour growth and enhance the 
chemotherapeutic effect of irinotecan in mouse models 
of CRC. Brusatol has been shown to inhibit Nrf2 and 
enhance chemosensitivity in a number of cancer cell 
lines [13, 15, 32]. However, recent work has indicated 
that brusatol blocks cap-dependent and -independent 
translation and provokes decreases in the levels of several 
short-lived proteins, in addition to Nrf2 [14, 33]. These 
findings are consistent with earlier work showing that 
quassinoids bind to the 80S ribosome, inhibiting protein 
elongation [34]. Therefore, whilst the inhibition of Nrf2 
may partly underlie the ability of brusatol to sensitise 
CRC cell lines to irinotecan and supress tumour growth in 
vivo, it is possible that effects on other critical mediators 
may also play a role. Alternatively, Chio et al. recently 
showed that Nrf2 regulates the activity of the translational 
machinery, with genetic disruption of Nrf2 in pancreatic 
cancer organoids causing defects in epidermal growth 
factor receptor signalling upstream of cap-dependent 
translation, as well as oxidation of specific translational 
regulatory proteins [35]. Therefore, the inhibition of Nrf2 
by brusatol may exacerbate its effect on translation of 
other proteins, although the transient nature of its effect 
on Nrf2 noted here and previously [13, 15] imply that this 
is not a perpetual cycle. As new inhibitors with greater 
specificity to Nrf2 emerge [36] it will be important to 
confirm the value of modulating Nrf2 per se in the context 
of CRC and other cancers.
Despite its reported impact on general protein synthesis, 
brusatol was well tolerated in our animal studies, with no 
adverse effects noted. Consistent with this, Lu et al. recently 
showed that daily administration of brusatol for 28 days could 
inhibit the growth of pancreatic cancer xenografts in mice in 
the absence of any changes in body weight or tissue injury 
biomarkers [32]. Extracts of the Brucea javanica plant, from 
which brusatol is derived, have been used in Chinese medicine 
to treat diseases including malaria and gastric ulcers [16]. Whilst 
this further supports the tolerability of natural quassinoids, to 
the best of our knowledge the exposure to brusatol in these 
settings has not been established through pharmacokinetic 
studies. Therefore, more work is necessary to fully establish the 
safety and therapeutic potential of brusatol in patients, yet this 
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Figure 5: The effects of Nrf2 modulation on tumour growth in vivo. (A) Example IVIS images of BALB/c mice from the brusatol 
treated and control groups after subcutaneous flank injection of the CT26lucA6c cell line. (B) Graphical display of the significant inhibition 
of tumour growth in mice treated with brusatol in comparison to vehicle treated controls (multiple t-tests, N=3/group, mean +/-SEM). (C) 
Photos of the flank tumours excised from mice (scale in 1mm increments) 21 days after implantation. (D) Western immunoblotting and 
densitometry confirmed significant inhibition of Nrf2 in the flank tumours excised from mice treated with brusatol (p=0.03, unpaired t-
test, bar chart displays mean and standard deviation). (E) Example serial IVIS® images of BALB/c mice orthotopically injected with the 
CT26lucA6c cell line with time from implantation of cells. (F) Data displayed graphically as fold change in luminescence from the first 
day of treatment. All treatments inhibited tumour growth significantly compared to mice in the control group (one-way ANOVA, N=8, 
graphs display mean +/- SEM). (G) Representative images from tissue stained for Nrf2 by IHC. Moderate to strong diffuse staining is 
demonstrated in the a) positive control of liver from BALB/c mice treated with CDDO-me. b) Livers from Nrf2 knockout mice were used 
as a negative control and were absent of Nrf2 staining. There was strong staining demonstrated in caecal tumours excised from mice in 
the c) control group and staining was reduced in the tumours from mice treated with d) brusatol. Graphical display of Nrf2 staining semi-
quantification reveals significantly (p=0.04 unpaired t-test with Welch’s correction) reduced Nrf2 staining semi-quantification in brusatol 
treated mice (N=3, graph displays mean +/- SD). C = control, BRU = brusatol, IR = irinotecan.
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study provides proof-of-concept that brusatol has beneficial 
effects in CRC. One approach to limiting possible systemic 
off-target effects of brusatol is to deliver it to tumours through 
the use of drug carriers [37] or chemo-embolisation [38]. In 
the context of mCRC, where irinotecan-based regimens may 
be the last available management option, the enhancement 
of irinotecan-based chemotherapy could overcome chemo-
resistance, improve treatment responses and allow dose 
reduction, which in turn could minimise adverse reactions 
and improve the wellbeing of patients.
MATERIALS AND METHODS
Immunohistochemical analysis in patient 
samples
NHS Research Ethics Committee and Research and 
Development approval was obtained for work on patient 
samples. Tissue microarrays were constructed from 
formalin-fixed paraffin embedded (FFPE) primary tumour, 
liver metastases and normal adjacent colonic mucosa from 
patients with metastatic CRC. Tissue cores were stained 
for Nrf2 expression using the primary antibody for Nrf2 
SC-722 (Santa Cruz, CA; 1:50 dilution; two hours) and 
semi-quantification of protein expression performed by 
Tissue Studio v.2.0 (Definiens AG, Munich, Germany). 
H-scores were calculated as described by Shousha [39]. 
See supplementary methods for additional details.
Cell culture
Human CRC (HCT116, European Collection of 
Cell Cultures) cells, murine BALB/c derived CRC (CT26, 
American Type Culture Collection) cells and normal 
immortalised human colonic cells (CCD-33Co, American 
Type Culture Collection) were cultured in DMEM, 
RPMI1640 and EMEM media respectively. Media were 
supplemented with 10% fetal bovine serum, 100 units/ml 
penicillin G and 100 μg/ml streptomycin. The luminescent 
CT26lucA6c clone was co-cultured with the selection 
antibiotic G-418 (Promega, Madison, WI).
Luminescent cells
CT26 cells were stably transfected with the 
pGL4.51 (Promega) plasmid using Lipofectamine® 2000 
(ThermoFisher, Waltham, MA) as per the manufacturer’s 
recommendations and selected via supplementation of the 
media with G-418 (Promega, Madison, WI). The most 
luminescent clone was passaged in the flank of an immune-
competent BALB/c mouse, producing CT26lucA6c cells.
Genetic modulation of Nrf2
siRNA targeting human NRF2 (siGenome 
D-003755-05, NM_001145413, Dharmacon, Lafayette, 
CO) or KEAP1 (siGenome D-012453-03, Nm_012289, 
Dharmacon); or murine Nrf2 (siGenome MQ-040766-
00, NM_010902, Dharmacon) or Keap1 (FlexiTube 
Mm_Keap1_7, NM_001110305, Qiagen, Venio, 
Netherlands) were used to modulate Nrf2 in the CRC 
cell lines. Transient transfections were performed using 
Lipofectamine® RNAiMAX (ThermoFisher), as per the 
manufacturer’s instructions. A non-targeting scrambled 
siRNA was used as a control in all experiments. Cells were 
transfected with siRNA for 48 h prior to application of 
chemotherapeutics or lysis for immunoblotting.
In vitro drug dosing and cell viability assay
Stock concentrations of all drugs, including 
irinotecan (J&H Chemical, Shanghai, China), 5-FU 
(Sigma-Aldrich, St. Louis, MI), CDDO-me (Cayman 
chemicals, Ann Arbor, MI) and brusatol (obtained as 
described previously [13]) were prepared in dimethyl 
sulfoxide (DMSO), serially-diluted and added to media. 
To assess the effect of Nrf2 modulation on chemo-
sensitivity, cells were either transfected with siRNA 48 h 
prior to the application of chemotherapeutics or co-dosed 
with CDDO-me or brusatol. Cell viability was assessed 
by introducing CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega, UK) to wells 2 h prior to 
analysis of light absorbance (490 nm) with a Varioskan™ 
reader. Results were calculated as a percentage of vehicle 
(0.5 % DMSO) treated cells. For western immunoblotting, 
cells were treated with CDDO-me or brusatol and lysed 
at the indicated time points for time-course experiments, 
or after three hours for dose-response analysis. All 
experiments were performed in triplicate on at least three 
occasions.
Western immunoblotting
Western immunoblotting was undertaken on 40 
micrograms of cell lysate and tumour tissue homogenate 
were loaded in Laemmli buffer (BioRad, Hercules, CA) 
on Mini-PRTOEAN® TGX™ Precast Gels (BioRad, 
Hercules, CA). After electrophoresis, proteins were 
transferred to nitrocellulose membranes and subject to 
immunoblot analysis using primary antibodies for Nrf2 
(Proteintech, Manchester, UK; 1:1000 dilution, 16396-
1-AP), NQO1 (Abcam, Cambridge, UK; 1:2000 dilution, 
ab28947) and actin (Abcam, Cambridge, UK; 1:10 000 
dilution, ab6726). Semi-quantitative densitometry was 
performed by Image-J v1.47 with samples normalised to 
actin.
Colony formation assay
Cells were exposed to vehicle control or brusatol for 
48 hours and then re-plated at 200 live cells/well on collagen 
coated plates. After 7-10 days colonies were fixed with 
methanol, stained with 0.5% crystal violet and counted using 
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GelCount™ (Oxford Optronix, Oxford, UK). The surviving 
fraction (SF) was calculated as a percentage of the vehicle 
control using the method described by Franken et al [40].
In vivo investigation
All animal experiments were performed under a 
UK Home Office approved project licence in a licenced 
establishment. BALB/c (Charles River, UK) mice were 
housed in a specific-pathogen-free environment on a 
12-hour light-dark cycle with free access to food and 
water. Brusatol treatment (2 mg/kg, see supplementary 
figures 1 for regimens) was compared to vehicle control 
(1% DMSO in phosphate buffered saline)following the 
subcutaneous injection of 5×105 CT26lucA6c cells. 
Mice were randomised to treatment arms seven days 
after the injection of cells, with calliper measurement 
and bioluminescence imaging used to quantify tumour 
progression. Bioluminescence imaging was performed 
using an IVIS Spectrum system (Perkin Elmer, Waltham, 
MA). Tumours were excised at the end of the study, 
homogenised in 0.1% sodium dodecyl sulfate / 0.5M 
triethylammonium bicarbonate buffer and subject to 
western immunoblotting.
An orthotopic syngeneic murine model of CRC 
was established by injecting 4×105 CT26lucA6c cells 
into the caecal sub-serosa as described previously 
[41] (see Supplementary Figure 1 for technique). 
Bioluminescent imaging of mice was utilised for the 
assessment of disease burden and mice with detectable 
signal randomised to treatment regimens: vehicle control, 
brusatol alone (2mg/kg), irinotecan alone (20mg/kg) 
or irinotecan plus brusatol (for dosing regimens see 
Supplementary Figure 1). Luminescent signals were 
quantified in photons/second and tumour growth expressed 
as fold change in luminescence from the first imaging 
day (i.e. pre-treatment), with each mouse acting as its 
own control. At the end of the study mice were sacrificed 
and tumour tissue stored in 4% paraformaldehyde 
prior to paraffin embedding for histological and 
immunohistochemical analyses.
IHC analysis of murine tumours
Sections of FFPE tumour blocks were stained 
for Nrf2 expression as described in the supplementary 
material. Livers from CDDO-me treated mice served as a 
positive control and from Nrf2 knockout mice a negative 
control [42]. Semi-quantification of Nrf2 expression 
was undertaken blinded to experimental conditions by 
multiplying the percentage of the Nrf2 positive cells by 
the Nrf2 stain intensity (1=mild; 2=moderate; 3=marked).
Statistical analysis
GraphPad Prism® 6 statistical software was utilised 
for dose-response analysis, calculation of inhibitory 
concentration (IC50) values and for comparisons of 
statistical significance. IC50 values were calculated by 
fitting a four-parameter log-concentration versus response 
curve to the data. Drug combinations were assessed for 
synergy using the Chou-Talalay method (combination 
index < 1 indicates synergy) and Compusyn software 
[43]. For mouse studies the slope of a line of best fit 
for each individual mouse was calculated as a surrogate 
marker of tumour growth rate. Growth rates for treatment 
groups were then compared to those in untreated controls 
with significance assessed by one-way ANOVA. SPSS 
statistics 21® was used to analyse patient data. A Shapiro-
Wilk normality test was used to select an appropriate 
statistical test. Statistical significance was assumed at a 
two-sided p value of <0.05 (*p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001).
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